来氟米特联合糖皮质激素治疗进展性IgA肾病的效果及对VCAM-1水平的影响

Abstract
Figure/Table
References (15)
Related Citation (5)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the Leflunomide combined with glucocorticoid on treating advanced IgA nephropathy and its influence on VCAM-1 level.MethodsFrom March 2015 to January 2017,108 advanced IgA nephropathy patients treated in our hospital were selected as research objects.According to their different therapeutic time,they were evenly divided into the treatment group and the control group,54 cases in each group.In the treatment group,Leflunomide combined with glucocorticoid was used,while in the control group,Prednisolone was applied.The therapeutic effect, detection indicators like serum,etc.,and adverse reactions after treatment in the two groups were recorded.ResultsAfter treatment,the total effective rate was 92.59%in the treatment group,which was higher than that in the control group (75.98%)(P＜0.05).After treatment,the urine protein content,serumalbumin content,serum creatinine content,glomerular filtration rate,and the level of VCAM-1 all tended to normal values,which were displayed statistical differences compared with before treatment(P＜0.05).There was significant difference in the urine protein content,serumalbumin content,serum creatinine content,glomerular filtration rate,and the level of VCAM-1 between the two groups after treatment(P＜0.05).The total adverse reaction rate in the treatment group was 18.52%,and 24.07%in the control group,there was no significant difference (P＞0.05).ConclusionCombination of Leflunomide and glucocorticoid in the treatment of progressive IgA nephropathy is effective,and it is helpful for the self-recovery of these patients and can greatly decrease VCAM-1 level.It is worthy to be promoted in clinical practice,which has a remarkable medical value and is of great significance.

Key words： Leflunomide Glucocorticoid Progressive IgA nephropathy VCAM-1 level

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHI Cai-lin

Cite this article:

SHI Cai-lin. Effect of Leflunomide combined with glucocorticoid in the treatment of advanced IgA nephropathy and its influence on VCAM-1 level[J]. 中国当代医药, 2017, 24(31): 80-82.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I31/80

[1]	李涛，冯爱桥，刘一卓，等.来氟米特联合糖皮质激素治疗进展性IgA肾病的研究[J].现代中西医结合杂志，2011，20（1）：13-15.
[2]	曾蕾，殷彩霞，黄雷招，等.来氟米特联合糖皮质激素对I-gA肾病患者疗效的影响[J].中国现代医生，2015，53（34）：21-24.
[3]	吴升芹，王建生.来氟米特联合糖皮质激素治疗IgA肾病疗效观察[J].中华实用诊断与治疗杂志，2014，28（5）：504-506.
[4]	施小俊，陈天浩.糖皮质激素联合来氟米特治疗IgA肾病的效果分析[J].临床医学研究与实践，2017，2（7）：29-30.
[5]	杨有芹，常晓东，程茂丽，等.来氟米特联合糖皮质激素治疗进展性IgA肾病的疗效及对VCAM-1水平的影响[J].现代生物医学进展，2016，16（11）：2134-2137.
[6]	耿坡.来氟米特、环磷酰胺联合糖皮质激素对系统性红斑狼疮患者肾功能与免疫功能的影响[J].中国医药导刊，2016，18（5）：506-507.
[7]	符月琴，白涛.来氟米特联合糖皮质激素治疗IgA肾病的Meta分析[J].中国药物与临床，2017，17（5）：745-748.
[8]	陈莉萍.来氟米特联合激素治疗难治性IgA肾病的临床观察研究[J].当代医学，2016，22（23）：118-119.
[9]	闵璐琳，张敏芳，车霞静，等.来氟米特联合中小剂量激素治疗IgA肾病的疗效观察[J].中华肾脏病杂志，2016，32（10）：721-727.
[10]	肖伟，任翔，任泽银.IgA肾病临床特点及治疗探析[J].当代医学，2013，（31）：68-69.
[11]	王颖，张宁，刘衍宁.来氟米特联合糖皮质激素治疗狼疮性肾炎的有效性及安全性研究[J].国际医药卫生导报，2015，21（18）：2747-2749.
[12]	杭永付，卢国元，沈蕾，等.来氟米特治疗IgA肾病安全性和有效性的Meta分析[J].中国临床药理学与治疗学，2017，22（1）：60-67.
[13]	张玉芳.来氟米特治疗IgA肾病的多中心临床探讨[J].临床医药文献杂志（电子版），2016，3（52）：10407.
[14]	范学礼.来氟米特联合糖皮质激素治疗难治性肾病综合征的效果分析[J].河南医学研究，2016，25（6）：1088-1089.
[15]	潘璐璐，蔡晖，周志宏，等.肾上腺糖皮质激素联合ACEI/ ARB治疗原发性IgA肾病的疗效观察[J].医学研究杂志，2015，44（8）：83-85.